Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
REAX heads into its October 29 earnings report having shed 16% in a single week, landing at $14.04, while the one analyst who just initiated coverage this morning slapped a $40 target on the stock.
That gap is the central tension. Citizens analyst James McCanless initiated with a Market Outperform rating and a $40 price target on October 14, the same day the stock closed near its worst levels of the past month. Jones Trading has held a matching $40 Buy target for weeks without moving. The consensus sits at roughly $31.58, and the stock trades at $14.04. That is a return potential above 100% at the mean target and well over 180% to the $40 targets. Bulls point to the franchise model's near-pure incremental margins, a synergy target the company says is running ahead of plan, and management's stated goal of reaching below 2.0x net leverage by end-2028. Bears counter with a simpler argument: the business is directly exposed to a cyclical US and Canadian housing market, and if rates stay elevated or unemployment rises, volumes and commission revenue fall quickly. The RE/MAX merger adds integration risk on top of a market that is already fragile.
Positioning in the lending market does not suggest much conviction from short sellers, despite the sharp weekly drop. Borrow availability is generous at roughly 290%, meaning nearly three shares are available to borrow for every share already on loan. The 52-week tightest reading was just 28.3%, so today's setup is far from stressed. Cost to borrow has roughly halved since early September, falling from above 2% to under 1%, confirming that demand for borrows has eased even as the stock has weakened. Short interest has crept up about 7% on the week in absolute share terms, but at around 1.47 million shares it remains a small position relative to the float. The ORTEX short score sits at 43, broadly mid-range and broadly flat on the week, consistent with a stock that is falling on fundamentals rather than short pressure. Options lean mildly bullish by recent standards, with the put/call ratio at 0.41 against a 20-day average of 0.46, and a z-score barely below zero. Calls are dominating flow, but the reading is not extreme.
The most structurally interesting near-term data point is the index rebalance picture. ORTEX forecasts a 90% probability that REAX joins both the S&P Completion and S&P TMI indices in the December 2026 Quarterly Review, with a rank date of November 16, an announcement date of December 4, and a trade date of December 18. Combined forced buying across the two indices would be approximately $28 million, representing roughly 0.6 days of normal trading volume. That is a modest flow in absolute terms but worth noting for a stock with a market cap near $193 million. These are ORTEX forecasts, not confirmed additions by S&P.
The activist register carries one name: David L. Liniger, who holds a 15.3% stake via a Schedule 13D filed September 24, making him the company's single largest holder and classifying him as an active filer. Liniger also sold just over 52,000 shares at roughly $19.12 each in mid-September, a transaction worth around $1 million, in his only open-market sale of the past 90 days. That sale was at prices considerably above where the stock trades today. The other recent insider transactions are option exercises and gifts, which carry little informational weight on direction. Institutional ownership is thin outside Liniger. BlackRock holds 2.5% and Vanguard Capital holds 2.3%, both with recent additions. The holder base totals just 29 institutional names.
Earnings history adds some context to the October 29 event risk. The August 14 print produced a 0.8% one-day move and a 10% gain over five days. An earlier August 6 result produced a 23.7% one-day gain and a 38.7% five-day gain. That second print was a genuine outlier, likely reflecting the merger completion or guidance update, but it illustrates that the stock can move dramatically in either direction on results. With the stock down 31% over the past month and analysts holding targets that are multiple times the current price, the October 29 print becomes as much a test of whether management's synergy and leverage narrative is intact as it is a question of the quarterly numbers themselves.
See the live data behind this article on ORTEX.
Open REAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.